False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations.

Autor: Fallah J; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD., Xu J; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD., Joeng HK; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD., Weinstock C; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD., Heiss BL; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD., Maguire WF; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD., Gao X; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD., Cheng J; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD., Chang E; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD., Agrawal S; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD., Fiero MH; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD., Pazdur R; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.; Oncology Center of Excellence (OCE), U.S. Food and Drug Administration, Silver Spring, MD., Kluetz PG; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.; Oncology Center of Excellence (OCE), U.S. Food and Drug Administration, Silver Spring, MD., Amiri-Kordestani L; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.; Oncology Center of Excellence (OCE), U.S. Food and Drug Administration, Silver Spring, MD., Suzman DL; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.

Publikováno v: JCO precision oncology [JCO Precis Oncol] 2024 Aug; Vol. 8, pp. e2400354.

Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.

Autor: Fallah J; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD., Xu J; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD., Weinstock C; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD., Gao X; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD., Heiss BL; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD., Maguire WF; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD., Chang E; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD., Agrawal S; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD., Tang S; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD., Amiri-Kordestani L; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.; Oncology Center of Excellence (OCE), U.S. Food and Drug Administration, Silver Spring, MD., Pazdur R; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.; Oncology Center of Excellence (OCE), U.S. Food and Drug Administration, Silver Spring, MD., Kluetz PG; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.; Oncology Center of Excellence (OCE), U.S. Food and Drug Administration, Silver Spring, MD., Suzman DL; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 May 10; Vol. 42 (14), pp. 1687-1698. Date of Electronic Publication: 2024 Mar 14.

Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors.

Autor: Maguire WF; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Schmitz JC; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA., Scemama J; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA., Czambel K; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA., Lin Y; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center Biostatistics Facility, Pittsburgh, PA, USA.; Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA., Green AG; Pitt Biospecimen Core Research Histology Department, Health Sciences Core Research Facilities, Pittsburgh, PA, USA., Wu S; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA.; School of Pharmaceutical Science, Southern Medical University, Guangzhou, China., Lin H; Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.; Roche Product Development, Roche (China) Holding Ltd., Shanghai, China., Puhalla S; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Rhee J; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Stoller R; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Tawbi H; Department of Melanoma and Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Lee JJ; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Wright JJ; Cancer Therapy Evaluation Program, National Cancer Institute, NIH, Bethesda, MD, USA., Beumer JH; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA., Chu E; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Department of Oncology and Cancer Therapeutics Program, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY, USA., Appleman LJ; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. applemanlj@upmc.edu.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA. applemanlj@upmc.edu.; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. applemanlj@upmc.edu.

Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2021 Oct; Vol. 88 (4), pp. 643-654. Date of Electronic Publication: 2021 Jun 23.

Remodeling the Vascular Microenvironment of Glioblastoma with α-Particles.

Autor: Behling K; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Maguire WF; Department of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York., Di Gialleonardo V; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Heeb LE; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Hassan IF; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Veach DR; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Keshari KR; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Gutin PH; Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Neurological Surgery, Weill Cornell Medical College, New York, New York., Scheinberg DA; Department of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Pharmacology, Weill Cornell Medical College, New York, New York; and., McDevitt MR; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York m-mcdevitt@ski.mskcc.org.; Department of Medicine, Weill Cornell Medical College, New York, New York.

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2016 Nov; Vol. 57 (11), pp. 1771-1777. Date of Electronic Publication: 2016 Jun 03.

Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for α-particle radioimmunotherapy of cancer.

Autor: Maguire WF; Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York Weill Cornell Medical College, New York, New York., McDevitt MR; Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York., Smith-Jones PM; Department of Psychiatry and Behavioral Science, Stony Brook University, Stony Brook, New York; and Department of Radiology, Stony Brook University, Stony Brook, New York., Scheinberg DA; Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York Weill Cornell Medical College, New York, New York Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York d-scheinberg@ski.mskcc.org.

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2014 Sep; Vol. 55 (9), pp. 1492-8. Date of Electronic Publication: 2014 Jun 30.